SLCO1A2

Across TCGA pan-cancer cohorts, SLCO1A2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SLCO1A2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SLCO1A2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SLCO1A2 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

LUAD, PDAC, and LSCC are the cancer types where SLCO1A2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLCO1A2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+0.303	<.001	8	view →
PDAC	Male	All	−0.489	<.001	6	view →
LSCC	Male	All	+0.267	<.001	6	view →
HNSC	Male	All	+0.199	.018	4	view →
CCRCC	All	All	−0.150	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SLCO1A2–LUAD

Open the LUAD breakdown →